Skip to Main Content

sickle cell

Sickle cell disease research news: STAT looks at new CRISPR-based treatment possibilities, and asks when sickle cell gene therapies will become widely available. For more on Oxbryta, Adakveo, hydroxyurea and IMR-687, read on.

Morning Rounds Newsletter

Biotech Jason Mast

STAT Plus: How sickle cell became the first disease treated by CRISPR

CRISPR has the potential to treat hundreds of diseases. STAT examines how sickle cell was the ideal test case for the gene-editing tool.

First Opinion Ted W. Love

STAT Plus: New attacks on the drug industry would have made my breakthrough sickle cell treatment impossible

In the Lab Megan Molteni

With CRISPR cures on horizon, sickle cell patients ask hard questions about who can access them

First Opinion Jennifer Fields

After living with sickle cell disease for 39 years, I’m both excited and skeptical about the newly approved gene therapies

Health Jonathan Wosen

STAT Plus: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease

All Coverage

Health Eric Boodman

Federal officials and physician groups express outrage over revelations of recent coercive sterilizations

A STAT Investigation Eric Boodman

The doctor would treat her sickle cell pain crisis — if she promised not to get an abortion

advertisement

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Listen: More tumult at BIO & coercive care for sickle cell patients

Don't Miss Rick Berke

A letter from the executive editor: Investigation reveals how doctors have pressured sickle cell patients into sterilizations

A STAT Investigation Eric Boodman

How doctors are pressuring sickle cell patients into unwanted sterilizations

Pharmalot Ed Silverman

STAT Plus: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies

Pharmalot Ed Silverman

STAT Plus: Pricey sickle cell treatments raise daunting new challenges for Medicaid programs

Health Jason Mast

After ‘SNL’ skit on sickle cell CRISPR therapy, advocates cite errors and stereotypes

Special Report Brittany Trang

STAT Plus: Gene therapy offered this 7-year-old freedom. The price: a grueling year

Biotech Jason Mast

STAT Plus: Could sickle cell someday be treated not with CRISPR, but with a pill?

First Opinion Robert Brodsky

New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists

Adam's Take Adam Feuerstein

STAT Plus: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale

Biotech Jonathan Wosen

STAT Plus: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH

Biotech Adam Feuerstein

STAT Plus: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

Biotech Adam Feuerstein

STAT Plus: In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease

Special Report Megan Molteni

New gene therapies confront many sickle cell patients with an impossible choice: a cure or fertility

Biotech Matthew Herper, Adam Feuerstein, Brittany Trang, and Eric Boodman

Key questions (and answers) about the historic approval of a CRISPR-based medicine

Biotech Andrew Joseph and Adam Feuerstein

STAT Plus: U.K. approves world’s first CRISPR-based medicine, giving green light to therapy for sickle cell, thalassemia

Biotech Megan Molteni and Adam Feuerstein

STAT Plus: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease

Biotech Adam Feuerstein and Megan Molteni

STAT Plus: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show

In the Lab Isabella Cueto

STAT Plus: Scientists inch closer to single-shot gene editing cure for blood disorders

Biotech Jason Mast

STAT Plus: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

First Opinion Jayasree K. Iyer

Sickle cell cures are coming. African children can’t be left behind

Biotech Andrew Joseph

STAT Plus: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy